BridgeBio Oncology Highlights BBO-8520 Tumor Responses and Combo Tolerability
BridgeBio Oncology emphasized its RAS-targeted pipeline leadership, highlighting BBO-8520’s demonstrated tumor responses and favorable safety profile in combination regimens during early clinical evaluation. These results support advancement of BBO-8520 into dose-expansion cohorts to further assess efficacy and tolerability.
1. BBO-8520 Clinical Data
BridgeBio Oncology presented early clinical data for BBO-8520 showing objective tumor responses in RAS-driven cancers and a favorable safety profile in combination regimens. The company is advancing BBO-8520 into dose-expansion cohorts to further evaluate efficacy and tolerability.
Related News
NVDA
NVIDIA Forecasts Zero China Data Center Revenue, Targets $20B Vera CPU Sales
NVDA•
AMD
AMD Pledges $10B Taiwan Investment for 2.5D EFB Packaging and Ramps 2nm “Venice” CPUs
AMD•
GOOG
Google Secures Tens of Thousands of MWh Storage as U.S. Energy Storage Hits Q1 Record
GOOG•
BLTE
Belite Bio Begins FDA NDA Rolling Submission, Q1 Loss Widens on $15.7M R&D
BLTE•
ODV
Osisko Development Raises US$275M via 4.125% Convertible Notes with 25% Premium
ODV•
Sources
F